CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China
Tuesday, July 04, 2023
CANbridge Pharmaceuticals has announced its plan to continue the Phase 2 study of CAN008 (asunercept) in patients with newly diagnosed glioblastoma multiforme (GBM) in China based on the recommendation of the independent data monitoring committee.
The Phase 2 study is a double-blinded trial that enrolled 119 subjects who were randomised to receive either intravenous CAN008 400 mg or a placebo in addition to standard-of-care chemoradiotherapy.
The treatment regimen included a 6-week course of triple therapy (temozolomide, radiotherapy, and CAN008 or placebo), followed by a 1-month rest, a 12-month course of dual therapy (temozolomide and CAN008 or placebo), and then monotherapy (CAN008 or placebo) until disease progression, intolerability to treatment, death, or withdrawal.
CAN008 is a CD95-Fc fusion protein that works by blocking the interaction between the CD95 ligand and the endogenous CD95 receptor. It has a dual mechanism of action, inhibiting tumour cell growth and migration while also enhancing immune recognition of the cancer by preventing T-cell apoptosis.
In China, CAN008 has been classified as a Class 1 New Drug by the National Medical Products Administration. Currently, they are conducting the Phase 2 trial of CAN008 in GBM in China.
Glioblastoma is a challenging cancer with limited treatment options and poor patient outcomes under standard-of-care. The development of CAN008 (asunercept) as a potential treatment for glioblastoma in China brings hope for improved outcomes for patients.
